� A recent report published in American Journal of Hematology demonstrated that Erythropoiesis-stimulating agents (ESAs), a widely used drug to treat anaemia, may get a minus impact on the endurance of myeloma patients. In the report, 323 multiple myeloma patients were evaluated over a 20 year period in Greece from 1988 to 2007. The investigators reviewed their medical records and observed an association betwixt ESA exposure and a reduction in progression-free and overall natural selection.
The study demonstrated that ESA disposal may influence the row of the disease, in that people who standard ESA may progress before than those who did not receive ESA. The median survival rate was 31 months for patients who were administered ESAs, compared to 67 months in those who were not uncovered to ESAs. The medial progression-free selection for patients in the ESA radical was 14 months, and 30 months for those without ESA exposure.
For the past 15 days,
